VCEL · Health Care

Vericel Corporation earnings

Latest results: Q3 2025 reported Nov 6, 2025

Vericel Corporation reported a record third quarter in 2025, driven by impressive revenue growth and significant profit improvements, highlighting strong momentum in its MACI and burn care products.

  • Third quarter total revenue reached a record $67.5 million, exceeding guidance, with MACI revenue increasing 25% year-over-year to $55.7 million.
  • Adjusted EBITDA margin stood at 25%, with GAAP net income surpassing $5 million and operating cash flow exceeding $22 million.
  • The launch of MACI Arthro has resulted in a substantial increase in biopsy growth, with over 800 trained surgeons, enhancing overall implant and revenue growth.

Next report: February 25, 2027 (estimated) · Earnings calendar

Your portfolio

Track earnings for the stocks you own

Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.